Yi Gong
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Immune Cellular Patterns Predicting Lymph Node Status Helps Personalized Management of Stage T1 Esophageal Squamous Cell Carcinoma.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: March 17, 2025
First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis.
Journal: Molecular cancer therapeutics
Published: February 29, 2024
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: December 01, 2022
Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
Journal: JAMA network open
Published: December 01, 2022
Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer.
Journal: Biomedical journal
Published: January 28, 2021
Knockdown of circRNA circ_0087378 Represses the Tumorigenesis and Progression of Esophageal Squamous Cell Carcinoma Through Modulating the miR-140-3p/E2F3 Axis.
Journal: Frontiers in oncology
Published: September 16, 2020
ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5p.
Journal: Pathology, research and practice
Published: September 29, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026